Active Biotech AB Interim Report January - March 2011

(Thomson Reuters ONE) -


* Laquinimod - complete results from Allegro Phase III trial presented
* TASQ - Active Biotech and Ipsen enter into a broad partnership for the co-
development and commercialization of TASQ in uro-oncology
* ANYARA - ongoing Phase III study expected to be concluded in 2012
* 57-57 - orphan drug status granted
* ISI - project proceeding according to plan
* RhuDex(TM) - preparations for continued clinical development in progress
* Net sales SEK 2.7 M (2.8)
* Operating loss SEK 70.9 M (loss: 51.0)
* Loss after tax SEK 69.3 (loss: 53.5)
* Loss per share for the period amounted to 1.02 (loss: 0.83)
* Private placement of SEK 375 M completed

For further information, please contact:

Tomas Leanderson
President and CEO
Tel: +46 (0)46-19 20 95

Göran Forsberg
VP Investor Relations & Business Development
Tel: +46 (0)46-19 11 54

Hans Kolam
CFO
Tel. +46 (0)46-19 20 44

Active Biotech AB
(Corp. Reg. No. 556223-9227)
PO Box 724, SE-220 07 Lund
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 11 00
This report is also available atwww.activebiotech.com




Active Biotech AB Interim Report January - March 2011:
http://hugin.info/1002/R/1509816/444684.pdf




This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.

Source: Active Biotech via Thomson Reuters ONE

[HUG#1509816]

Weitere Infos zu dieser Pressemeldung:
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
Datum: 28.04.2011 - 08:30 Uhr
Sprache: Deutsch
News-ID 53977
Anzahl Zeichen: 1960

contact information:
Town:

LUND

Kategorie:

Business News

Diese Pressemitteilung wurde bisher 179 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Active Biotech AB Interim Report January - March 2011"
steht unter der journalistisch-redaktionellen Verantwortung von

Active Biotech (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Primary endpoint reached in Active Biotech's TASQ Phase II clinical trial i ...

Lund, Sweden, December 14, 2009 - A first analysis of the primary endpoint based on data from at least six months' treatment of more than 200 patients, has been performed in Active Biotech AB's (NASDAQ OMX Nordic: ACTI) ongoing Phase II cli ...

Active Biotech's election committee appointed ...

In accordance with a decision made by the Annual General Meeting held on May 7, 2009, the Election Committee shall comprise the representatives for the three largest shareholders on September 30 and the Board Chairman. For the 2010 Annual General ...

Active Biotech AB Interim Report, January - September 2009 ...

* Laquinimod -- new data presented at ECTRIMS * 57-57 -- exploratory clinical trial in progress * RhuDex(TM) -- clinical development to continue following feedback from UK MHRA * ANYARA -- complete Phase I data published * TASQ -- complete Phase I ...

Alle Meldungen von Active Biotech